Products with Antagonists bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5127 | Cannabigerol |
| 1. Cannabigerol has antimicrobial and antifungal activity. 2. Cannabigerol can treat inflammatory bowel disease. 3. Cannabigerol can relieve interocular pressure, which may be of benefit in the treatment of glaucoma. 4. Cannabigerol is a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also binds to the CB2 receptor. 5. Cannabigerol exhibits the highest growth-inhibitory activity against the cancer cell lines. 6. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. | |
| BCN5218 | Harmaline |
| Harmaline is a central nervous system stimulant and an acetylcholinesterase (AChR) inhibitor; also inhibits histamine N-methyltransferase. Harmaline has antileishmanial, bioinsecticidal, and vasorelaxant effects. It has antagonist effects on alpha1-adrenorecepteors in non-competitive manner, it also exerts an antioxidant activity by scavenging the free radical generated by DPPH.Harmaline may prevent dopamine-induced mitochondrial damage and PC12 cell death through a scavenging action on reactive oxygen species and inhibition of monoamine oxidase and thiol oxidation. | |
| BCN5228 | gamma-Mangostin |
| gamma-Mangostin is a dual agonist that activates both PPARδ and PPARα, is also a novel competitive antagonist for the 5-HT2A receptors in vascular smooth muscles and platelets.gamma-Mangostin has free radical scavenging activity, and antiproliferative and apoptotic activity in HepG2 cells, and exhibits antihypertensive, anti-inflammatory, analgesic effects. gamma-Mangostin could as a preventive agent of the metabolic syndrome, and could serve as a micronutrient for colon cancer prevention. | |
| BCN5236 | Pinusolide |
| 1. Pinusolide is a platelet activating factor ( PAF) antagonist, it may prove of therapeutic value in the treatment of hypotension . 2. Pinusolide has antileukemic potential, it not only decreases the proliferation activity of tumor cells at relatively low concentrations but specifically induces apoptosis at 100 microM via the mitochondrial pathway in the Burkitt lymphoma cell line BJAB. 3. Pinusolide attenuates blockade of insulin signaling by enhancing IRS-1 tyrosine phosphorylation by the activating the AMPK pathway, indicates the targeting of AMPK represents a new therapeutic strategy for hyperglycemia-induced insulin resistance and type 2 diabetes. 4. Pinusolide can protect neuronal cells from staurosporine (STS) -induced apoptosis, probably by preventing the increase in [Ca2+]i and cellular oxidation caused by STS, and indicate that it could be used to treat neurodegenerative diseases. 5. Pinusolide shows potent inhibition of 5-LO dependent LTC4 generation, which requires both suppression of calcium influx and JNK phosphorylation. | |
| BCN5532 | Liriodenine |
| 1. Liriodenine has antibacterial and antifungal activity. 2. Liriodenine inhibits progression of the CAOV-3 cell cycle in S phase. 3. Liriodenine exhibits potent antitumor activities in laryngocarcinoma HEp-2 cells, in vitro and in vivo, via the upregulation of p53 expression. 4. Liriodenine is a potent inhibitor of topoisomerase II (EC 5.99.1.3) both in vivo and in vitro. 5. Liriodenine can suppress ventricular arrhythmias induced by myocardial ischaemia reperfusion, through inhibition of Na+ and the Ito channel. 6. Liriodenine has antimuscarinic properties, the antimuscarinic characteristics are similar to those of 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, smooth muscle selective M3 antagonist), it may act as a selective M3 receptor antagonist in canine tracheal smooth muscle. | |
